Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

25.77 -0.27 (-1.02%)
Streaming Delayed Price Updated: 10:52 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗
Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗
Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies. 
Via Chartmill
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Insights into Immunovant's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Four Stocks To Watch This Week - Monday, Sep. 23 ↗
For this week, we expect a slight pause in momentum, though nothing particularly dramatic. 
Via Talk Markets
News headline image
Top 2 Health Care Stocks That May Collapse This Quarter ↗
 
Via Benzinga
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Immunovant Stock Blasted Higher Today ↗
The biotech looks as if it has a promising treatment for an autoimmune disorder. 
Via The Motley Fool
News headline image
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Immunovant Posts 34% R&D Jump in Q1 ↗
Via The Motley Fool
News headline image
IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Via ACCESS Newswire
News headline image
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗
The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share. 
Via Stocktwits
News headline image
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗
The company is getting a new chief executive and a new chief financial officer amid sweeping changes. 
Via Investor's Business Daily
Topics Government
News headline image
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 
Via Stocktwits
Topics Government Retirement Stocks
News headline image
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402. 
Via Benzinga
News headline image
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗
The companies reported positive results for their lead asset in patients with two rare diseases. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
News headline image
High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What ↗
With inflation and jobs behind us, it’s time to shift our focus 6,700 miles west to Tokyo. The Bank of Japan appears poised for another rate hike next week, with odds now at 77%. Monitor the VIX for... 
Via Talk Markets
Topics Economy Stocks
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? ↗
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... 
Via Benzinga
News headline image
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
News headline image
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.